Iron chelators induce autophagic cell death in multiple myeloma cells

Leuk Res. 2014 Aug;38(8):988-96. doi: 10.1016/j.leukres.2014.06.005. Epub 2014 Jun 17.

Abstract

We examined the antineoplastic effects of the iron chelators, deferasirox and deferoxamine in multiple myeloma cell lines as well as primary myeloma cells. These iron chelators showed marked antiproliferative activity as well as cytotoxicity toward myeloma cell lines and deferasirox was cytotoxic to bone marrow plasma cells from myeloma patients. We also demonstrate that autophagy induced by iron deprivation is the dominant mechanism that mediates the cytotoxicity of iron chelators in multiple myeloma. Exposure to iron chelators led to repression of mTOR signaling as evidenced by decreased phosphorylation of its target p70S6 kinase. Iron chelation, in particular with deferasirox has the potential to be readily translated to a clinical trial for multiple myeloma.

Keywords: Autophagy; Deferasirox; Deferoxamine; Iron chelation; Multiple myeloma; mTOR; p70S6 kinase.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Autophagy / drug effects*
  • Benzoates / pharmacology*
  • Benzoates / therapeutic use
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Deferasirox
  • Deferoxamine / pharmacology*
  • Deferoxamine / therapeutic use
  • Drug Evaluation, Preclinical
  • Humans
  • Iron Chelating Agents / pharmacology*
  • Iron Chelating Agents / therapeutic use
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology*
  • Primary Cell Culture
  • Reactive Oxygen Species / metabolism
  • Triazoles / pharmacology*
  • Triazoles / therapeutic use

Substances

  • Benzoates
  • Iron Chelating Agents
  • Reactive Oxygen Species
  • Triazoles
  • Deferoxamine
  • Deferasirox